Dewpoint Therapeutics Doses First Patient in Phase 1a/2a Trial DPTX3186 for the Treatment of Advanced Solid Tumors, Focused on Gastric Cancer
DPTX3186, a first-in-class beta-catenin condensate modulator, received Orphan Drug Designation and Fast…
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2026 16:05 ET | Source: Candel Therapeutics NEEDHAM, Mass., Feb.…
Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit
TONMYA demonstrated significant reduction in fibromyalgia pain compared with placebo in the…
Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease
Nine-month findings show mean improvement in Composite Unified Huntington's Disease Rating Scale…
BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema
January 23, 2026 09:00 ET | Source: BioCryst Pharmaceuticals, Inc. RESEARCH TRIANGLE…
Vivos Therapeutics Announces Closing of Exercise of Warrants for $4.64 Million Gross Proceeds
January 20, 2026 17:31 ET | Source: Vivos Therapeutics, Inc LITTLETON, Colo.,…
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 16, 2026 16:05 ET | Source: Context Therapeutics Inc. PHILADELPHIA, Jan.…
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 16, 2026 16:05 ET | Source: CAMP4 Therapeutics CAMBRIDGE, Mass., Jan.…
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte…
Onco3R Therapeutics Appoints Lawrence Blatt as Chair of the Board for Onco3R Therapeutics
Leuven, Belgium. January 8, 2026. Onco3R Therapeutics, a clinical-stage immunology and oncology…
